0.9692
price up icon9.32%   0.082
 
loading
전일 마감가:
$0.8872
열려 있는:
$0.9
하루 거래량:
8.80M
Relative Volume:
2.14
시가총액:
$282.95M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-3.5896
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
+16.27%
1개월 성능:
+27.62%
6개월 성능:
+11.70%
1년 성능:
-46.41%
1일 변동 폭
Value
$0.90
$1.01
1주일 범위
Value
$0.80
$1.01
52주 변동 폭
Value
$0.515
$1.979

오큐젠 Stock (OCGN) Company Profile

Name
명칭
Ocugen Inc
Name
전화
484-328-4701
Name
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Name
직원
95
Name
트위터
@Ocugen
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
OCGN's Discussions on Twitter

OCGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
OCGN
Ocugen Inc
0.9689 257.98M 0 -63.08M -72.53M -0.27
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.18 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
446.12 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.29 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.92 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
487.39 63.90B 14.09B 4.50B 2.96B 39.28

오큐젠 Stock (OCGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-10-15 개시 Maxim Group Buy
2023-03-01 업그레이드 Chardan Capital Markets Neutral → Buy
2022-08-23 개시 Mizuho Buy
2022-06-15 재개 ROTH Capital Buy
2022-06-02 개시 Cantor Fitzgerald Overweight
2021-07-26 개시 Noble Capital Markets Outperform
2021-06-11 다운그레이드 ROTH Capital Buy → Neutral
2021-05-07 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2021-02-09 다운그레이드 Chardan Capital Markets Buy → Neutral
2021-02-04 업그레이드 H.C. Wainwright Neutral → Buy
모두보기

오큐젠 주식(OCGN)의 최신 뉴스

pulisher
10:40 AM

Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times

10:40 AM
pulisher
10:36 AM

Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com India

10:36 AM
pulisher
10:31 AM

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus

10:31 AM
pulisher
09:32 AM

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

09:32 AM
pulisher
08:20 AM

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - marketscreener.com

08:20 AM
pulisher
07:59 AM

Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia

07:59 AM
pulisher
07:41 AM

Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada

07:41 AM
pulisher
07:24 AM

Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks

07:24 AM
pulisher
07:23 AM

Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com

07:23 AM
pulisher
07:16 AM

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus

07:16 AM
pulisher
07:15 AM

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | OCGN Stock News - GuruFocus

07:15 AM
pulisher
07:03 AM

Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire

07:03 AM
pulisher
07:02 AM

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

07:02 AM
pulisher
07:01 AM

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph

07:01 AM
pulisher
02:07 AM

OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - mx.advfn.com

02:07 AM
pulisher
Jun 02, 2025

Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today

Jun 02, 2025
pulisher
Jun 01, 2025

Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN

Jun 01, 2025
pulisher
May 31, 2025

Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN

May 31, 2025
pulisher
May 29, 2025

FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -

May 29, 2025
pulisher
May 28, 2025

Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®

May 28, 2025
pulisher
May 28, 2025

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN

May 28, 2025
pulisher
May 27, 2025

FDA grants Ocugen rare pediatric disease designation as voucher program remains in limbo - The Business Journals

May 27, 2025
pulisher
May 27, 2025

Ocugen Gets FDA Rare Pediatric Disease Label for OCU410ST - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therap - GuruFocus

May 27, 2025
pulisher
May 27, 2025

FDA grants Ocugen’s OCU410ST rare pediatric disease status By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - Ocugen

May 27, 2025
pulisher
May 27, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted for - GuruFocus

May 27, 2025
pulisher
May 27, 2025

FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

FDA Grants Rare Pediatric Disease Designation to OCU410ST from Ocugen (OCGN) | OCGN Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Ocugen receives Rare Pediatric Disease Designation for OCU410ST - TipRanks

May 27, 2025
pulisher
May 27, 2025

Ocugen Announces Rare Pediatric Disease Designation Granted - GlobeNewswire

May 27, 2025
pulisher
May 27, 2025

FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood BlindnessNo Current Treatment Exists - Stock Titan

May 27, 2025
pulisher
May 27, 2025

Northern Trust Corp Acquires 227,150 Shares of Ocugen, Inc. (NASDAQ:OCGN) - Defense World

May 27, 2025
pulisher
May 20, 2025

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish - MSN

May 20, 2025
pulisher
May 19, 2025

Ocugen, Inc. (NASDAQ:OCGN) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 19, 2025
pulisher
May 16, 2025

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN

May 16, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Has $32,000 Position in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

May 16, 2025
pulisher
May 15, 2025

Ocugen Provides Business Update with First Quarter 2025 Financial Results - ADVFN

May 15, 2025
pulisher
May 15, 2025

Noble Financial Predicts Ocugen’s Q2 Earnings (NASDAQ:OCGN) - Defense World

May 15, 2025
pulisher
May 14, 2025

Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9 - MSN

May 14, 2025
pulisher
May 13, 2025

Ocugen stock price target cut to $7 by H.C. Wainwright - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Ocugen (NASDAQ:OCGN) Receives Buy Rating from Chardan Capital - Defense World

May 13, 2025
pulisher
May 12, 2025

Ocugen (OCGN) Receives Ongoing "Buy" Rating from Chardan Capital - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Ocugen (OCGN) Maintains 'Buy' Rating Despite Price Target Adjust - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Ocugen (OCGN) Price Target Reduced by H.C. Wainwright | OCGN Sto - GuruFocus

May 12, 2025
pulisher
May 12, 2025

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Ocugen outlines 2025 milestones for gene therapy programs with BLA filings on track - MSN

May 12, 2025
pulisher
May 11, 2025

Barclays PLC Decreases Holdings in Ocugen, Inc. (NASDAQ:OCGN) - Defense World

May 11, 2025
pulisher
May 10, 2025

Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Ocugen: Q1 Earnings Snapshot - New Haven Register

May 10, 2025
pulisher
May 10, 2025

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo

May 10, 2025

오큐젠 (OCGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

오큐젠 주식 (OCGN) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Castillo Kirsten
Director
Nov 22 '24
Buy
0.91
25,000
22,848
75,000
$1.15
price up icon 0.00%
$575.14
price up icon 0.19%
$301.34
price down icon 0.24%
$36.38
price up icon 0.37%
$4.75
price down icon 2.11%
$478.00
price down icon 0.60%
자본화:     |  볼륨(24시간):